CAB-ROR2-ADC (BA-3021)
Ovarian Cancer
Canadian Cancer Trials Groupantibody_drug_conjugatePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 59/ 100
Competitive context
524 Active assets in the Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tisotumab Vedotin Seagen Inc. | Phase 2 | BB |
TIL Inge Marie Svane | Phase 2 | BB |
Olaparib Shandong University | Phase 4 | BB |
Carboplatin Fudan University | Phase 4 | BB |
Irinotecan ARCAGY/ GINECO GROUP | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →